Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

DRCR.Net Aflibercept vs. Bevacizumab + Aflibercept diferido para o tratamento de CI-DME (DRCR AC)

9 de setembro de 2026 atualizado por: Jaeb Center for Health Research

Ensaio randomizado de aflibercept intravítreo versus bevacizumabe intravítreo + aflibercept diferido para tratamento de edema macular diabético com envolvimento central

Both aflibercept and bevacizumab have been shown to improve vision in eyes with DME. In eyes with DME and at least moderate vision loss, both aflibercept and bevacizumab were also shown to be successful in many eyes. However, aflibercept was shown to be more effective at improving vision, on average, at 1 year and at 2 years. Due to the large cost difference between the two drugs, many clinicians and patients are choosing to initiate treatment with bevacizumab and then switch to aflibercept depending on the eye's response to bevacizumab treatment. However, there is no scientific evidence that this treatment strategy is as effective at improving vision as initiating treatment with aflibercept. Patients and clinicians do not know if this approach ultimately has deleterious effects on visual acuity. If starting with aflibercept is not better than starting with bevacizumab and switching to aflibercept if needed, the potential cost savings to future patients and the health care system would be substantial. However, if starting with aflibercept is better, then patients, clinicians, and health care providers can make informed decisions for how to best treat patients with DME and at least moderate vision loss.

Study Objectives To compare the efficacy of intravitreous aflibercept with intravitreous bevacizumab + deferred aflibercept if needed in eyes with CI DME and moderate vision loss

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

270

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • California
      • Campbell, California, Estados Unidos, 95008
        • Retinal Diagnostic Center
      • Glendale, California, Estados Unidos, 91203
        • Macula & Retina Institute
      • Loma Linda, California, Estados Unidos, 92354
        • Loma Linda University Health Care, Department of Ophthalmology
      • Oakland, California, Estados Unidos, 94609-3028
        • East Bay Retina Consultants, Inc
    • Florida
      • Fort Myers, Florida, Estados Unidos, 33912
        • National Ophthalmic Research Institute
      • Jacksonville, Florida, Estados Unidos, 32216
        • Florida Retina Institute-Jacksonville
      • Lakeland, Florida, Estados Unidos, 33805
        • Florida Retina Consultants
      • Miami, Florida, Estados Unidos, 33126
        • Retina Macula Specialists of Miami
      • Orlando, Florida, Estados Unidos, 32806
        • Florida Retina Institute
      • Orlando, Florida, Estados Unidos, 32806
        • Central Florida Retina
      • Pinellas Park, Florida, Estados Unidos, 33782
        • Southeast Eye Institute, P.A. dba Eye Associates of Pinellas
      • Plantation, Florida, Estados Unidos, 33324
        • Fort Lauderdale Eye Institute
      • Sarasota, Florida, Estados Unidos, 34239
        • Sarasota Retina Institute
      • Sarasota, Florida, Estados Unidos, 34233
        • Retina Associates of Sarasota
      • Tampa, Florida, Estados Unidos, 33609
        • Retina Associates of Florida, LLC
      • Wesley Chapel, Florida, Estados Unidos, 33544
        • Retina Specialists of Tampa
    • Georgia
      • Augusta, Georgia, Estados Unidos, 30909
        • Southeast Retina Center, P.C.
      • Sandy Springs, Georgia, Estados Unidos, 30328
        • Thomas Eye Group
    • Illinois
      • Oak Park, Illinois, Estados Unidos, 60304
        • Illinois Retina Associates, S.C.
      • Springfield, Illinois, Estados Unidos, 62703
        • Springfield Clinic, LLP
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46290
        • Raj K. Maturi, M.D., P.C.
      • New Albany, Indiana, Estados Unidos, 47150
        • John-Kenyon American Eye Institute
    • Kansas
      • Overland Park, Kansas, Estados Unidos, 66211
        • Mid-America Retina Consultants, P.A.
      • Shawnee Mission, Kansas, Estados Unidos, 66204
        • Retina Associates, P.A.
    • Kentucky
      • Paducah, Kentucky, Estados Unidos, 42001
        • Paducah Retinal Center
    • Louisiana
      • West Monroe, Louisiana, Estados Unidos, 71291
        • Eye Associates of Northeast Louisiana dba Haik Humble Eye Center
    • Maryland
      • Hagerstown, Maryland, Estados Unidos, 21740
        • Mid Atlantic Retina Specialists
    • Massachusetts
      • Ayer, Massachusetts, Estados Unidos, 01432
        • Valley Eye Physicians and Surgeons
      • Boston, Massachusetts, Estados Unidos, 02215
        • Joslin Diabetes Center
    • Michigan
      • Grand Rapids, Michigan, Estados Unidos, 49546
        • Vitreo-Retinal Associates
      • Grand Rapids, Michigan, Estados Unidos, 49546
        • Retina Specialists of Michigan
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63128
        • The Retina Institute
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87109
        • Eye Associates of New Mexico
    • New York
      • New York, New York, Estados Unidos, 10021
        • MaculaCare
      • Rochester, New York, Estados Unidos, 14620
        • Retina Associates of Western New York
    • North Carolina
      • Asheville, North Carolina, Estados Unidos, 28803
        • Western Carolina Clinical Research, LLC
      • Charlotte, North Carolina, Estados Unidos, 28210
        • Charlotte Eye, Ear, Nose and Throat Assoc., PA
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44106
        • University Hospitals Cleveland Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • Dean A. McGee Eye Institute
    • Oregon
      • Portland, Oregon, Estados Unidos, 97221
        • Retina Northwest, PC
      • Springfield, Oregon, Estados Unidos, 97477
        • Cascade Medical Research Institute, LLC
    • Pennsylvania
      • Monroeville, Pennsylvania, Estados Unidos, 15146
        • Retina Vitreous Consultants
      • Philadelphia, Pennsylvania, Estados Unidos, 19107-5109
        • Retinavitreous Associates, dba; Mid Atlantic Retina
    • Tennessee
      • Knoxville, Tennessee, Estados Unidos, 37909
        • Southeastern Retina Associates, P.C.
    • Texas
      • Austin, Texas, Estados Unidos, 78705
        • Austin Retina Associates
      • Austin, Texas, Estados Unidos, 78705
        • Retina Research Center
      • Grapevine, Texas, Estados Unidos, 76051
        • Retina Center of Texas
      • Houston, Texas, Estados Unidos, 77030
        • Retina Consultants of Houston, PA
      • Houston, Texas, Estados Unidos, 77030
        • Baylor Eye Physicians and Surgeons
      • Lubbock, Texas, Estados Unidos, 79424
        • Texas Retina Associates
      • McAllen, Texas, Estados Unidos, 78503
        • Valley Retina Institute
      • San Antonio, Texas, Estados Unidos, 78240
        • Retinal Consultants of San Antonio
    • Washington
      • Spokane, Washington, Estados Unidos, 99204
        • Spokane Eye Clinic
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Medical College of Wisconsin

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Participant-level Criteria Inclusion

To be eligible, the following inclusion criteria must be met:

  1. Age ≥ 18 years • Individuals <18 years old are not being included because DME is so rare in this age group that the diagnosis of DME may be questionable.

  2. Diagnosis of diabetes mellitus (type 1 or type 2)

    • Any one of the following will be considered to be sufficient evidence that diabetes is present:

    Current regular use of insulin for the treatment of diabetes Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes Documented diabetes by American Diabetes Association and/or World Health Organization criteria

  3. At least one eye meets the study eye criteria listed.

  4. Able and willing to provide informed consent.

    Exclusion

    An individual is not eligible if any of the following exclusion criteria are present:

  5. Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.

  6. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).

    • Individuals in poor glycemic control who, within the last four months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next four months should not be enrolled.
  7. Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied at the time of study entry.

    • Note: study participants cannot receive another investigational drug while participating in the study.

  8. Known allergy to any component of the study drug or any drug used in the injection prep (including povidone iodine prep).

  9. Blood pressure > 180/110 (systolic above 180 OR diastolic above 110).

    • If blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible.

  10. Systemic anti-VEGF or pro-VEGF treatment within four months prior to randomization or anticipated use during the study.

    • These drugs cannot be used during the study.

  11. For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 24 months.

    • Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment is used to determine when a pregnancy test is needed.

  12. Individual is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the next two years.

Study Eye Criteria The study participant must have at least one eye meeting all of the inclusion criteria and none of the exclusion criteria listed below.

Study participants can have two study eyes only if both eyes are eligible at the time of randomization. For study participants with two eligible eyes, the logistical complexities of the protocol must be considered for each individual prior to randomizing both eyes.

The eligibility criteria for a study eye are as follows:

Inclusion

  1. Best corrected Electronic-Early Treatment Diabetic Retinopathy Study visual acuity letter score < 69 (i.e., 20/50 or worse) and ≥ 24 (i.e., 20/320 or better) within eight days of randomization.

  2. On clinical exam, definite retinal thickening due to diabetic macular edema involving the center of the macula.

  3. Diabetic macular edema present on optical coherence tomography (OCT) within eight days of randomization

    • Zeiss Cirrus central subfield: ≥ 290µm in women or ≥ 305µm in men
    • Heidelberg Spectralis central subfield: ≥ 305µm in women or ≥ 320µm in men
    • Investigator must verify accuracy of OCT scan by ensuring it is centered and of adequate quality
  4. Media clarity, pupillary dilation, and individual cooperation sufficient for adequate fundus photographs.

    Exclusions

    The following exclusions apply to the study eye only (i.e., they may be present for the nonstudy eye):

  5. Macular edema is considered to be due to a cause other than diabetic macular edema.

    • An eye should not be considered eligible if: (1) the macular edema is considered to be related to ocular surgery such as cataract extraction or (2) clinical exam and/or OCT suggest that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema.

  6. An ocular condition is present such that, in the opinion of the investigator, visual acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition).

  7. An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.).

  8. Substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by three lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal).

  9. History of an anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema (DME) in the past 12 months or history of any other treatment for DME at any time in the past four months (such as focal/grid macular photocoagulation, intravitreous or peribulbar corticosteroids).

    • Enrollment will be limited to a maximum of 25% of the planned sample size with any history of anti-VEGF treatment for DME. Once this number of eyes has been enrolled, any history of anti-VEGF treatment for DME will be an exclusion criterion.

  10. History of pan-retinal photocoagulation within four months prior to randomization or anticipated need for pan-retinal photocoagulation in the six months following randomization.

  11. History of anti-VEGF treatment for a disease other than DME in the past 12 months.

  12. History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior four months or anticipated within the next six months following randomization.

  13. History of YAG capsulotomy performed within two months prior to randomization.

  14. Aphakia.

  15. Exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis.

  16. Evidence of uncontrolled glaucoma. • Intraocular pressure must be <30, with no more than one topical glaucoma medication, and no documented glaucomatous field loss for the eye to be eligible

Note, combination therapies are considered more than one medication

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Aflibercept Group

2.0 mg intravitreous aflibercept

Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.

Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.

Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.

The injection will be performed using sterile technique

Outros nomes:
  • Eylea
Experimental: Bevacizumab + Deferred Aflibercept Group

1.25 mg intravitreous bevacizumab + deferred intravitreous 2.0 mg aflibercept if eye meets switch criteria

Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.

Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.

Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.

The injection will be performed using sterile technique

Outros nomes:
  • Eylea

Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.

Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc.

Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.

The injection will be performed using a sterile technique.

Outros nomes:
  • AvastinName

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Mean Change in Visual Acuity
Prazo: 2 years

Area under the curve mean change in the electronic early treatment diabetic retinopathy study visual acuity. Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision. The data presented are the best-corrected visual acuity in the study eye after protocol-defined refraction. The primary outcome was the time-averaged change in the visual-acuity letter score over a period of 104 weeks. The score was derived by calculating the area under the curve (AUC) over the 104-week period for the change in visual acuity from baseline and dividing by the length of follow-up.

2 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Número de visitas
Prazo: 2 anos
2 anos
Número de olhos no primeiro grupo de bevacizumabe que atende aos critérios de troca
Prazo: Linha de base até 12 semanas
Linha de base até 12 semanas
Número de olhos no primeiro grupo de bevacizumabe que atende aos critérios de troca
Prazo: Linha de base até 24 semanas
Linha de base até 24 semanas
Número de olhos no primeiro grupo de bevacizumabe que atende aos critérios de troca
Prazo: Linha de base até 52 semanas
Linha de base até 52 semanas
Número de olhos no primeiro grupo de bevacizumabe que atende aos critérios de troca
Prazo: Linha de base até 104 semanas
Linha de base até 104 semanas
Change in Visual Acuity From Baseline
Prazo: 2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Increase in E-ETDRS Visual Acuity Letter Score
Prazo: 2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Decrease in E-ETDRS Visual Acuity Letter Score
Prazo: 2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Visual Acuity
Prazo: 2 years

Visual acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study visual-acuity test on a scale from 100 letters (Snellen equivalent, 20/10) to 0 letters (Snellen equivalent, <20/800), with higher scores indicating better vision.

2 years
Optical Coherence Tomography Central Subfield Thickness Change From Baseline
Prazo: 2 years

Measurements made on the Cirrus device were converted to equivalent scores as would be assessed on the Spectralis device with the use of the following formula: Spectralis score = 40.78 + 0.95 × Cirrus score.

2 years
Optical Coherence Tomography Central Subfield Thickness Below the Sex-specific Threshold for Central-involved Diabetic Macular Edema
Prazo: 2 years

Optical coherence tomography (OCT) central subfield thickness equivalents for measurements obtained on Spectral domain OCT machines were 320 μm for men and 305 μm for women on the Spectralis device (Heidelberg) and were 305 μm and 290 μm, respectively on the Cirrus OCT measurement device (Zeiss).

2 years
Number of Injections
Prazo: 2 years

All study injections were counted, including aflibercept injections received among eyes in the bevacizumab first group.

2 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

7 de dezembro de 2017

Conclusão Primária (Real)

22 de dezembro de 2021

Conclusão do estudo (Real)

22 de dezembro de 2021

Datas de inscrição no estudo

Enviado pela primeira vez

23 de outubro de 2017

Enviado pela primeira vez que atendeu aos critérios de CQ

23 de outubro de 2017

Primeira postagem (Real)

25 de outubro de 2017

Atualizações de registro de estudo

Última Atualização Postada (Real)

1 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever